{"name":"Elixiron Immunotherapeutics (Hong Kong) Ltd.","slug":"elixiron-immunotherapeutics-hong-kong-ltd","ticker":"","exchange":"","domain":"elixironimmunotherapeuticshongkong.com","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"Pharma / Biotech","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Oncology","slug":"oncology","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"EI-001","genericName":"EI-001","slug":"ei-001","indication":"Metastatic non-small cell lung cancer, PD-L1 positive","status":"phase_2"}]},{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"immunology","drugs":[{"name":"EI-1071 tablet, oral","genericName":"EI-1071 tablet, oral","slug":"ei-1071-tablet-oral","indication":"Other","status":"phase_2"}]}],"pipeline":[{"name":"EI-001","genericName":"EI-001","slug":"ei-001","phase":"phase_2","mechanism":"EI-001 is an immunomodulatory agent that targets the PD-1/PD-L1 axis.","indications":["Metastatic non-small cell lung cancer, PD-L1 positive","Metastatic melanoma"],"catalyst":""},{"name":"EI-1071 tablet, oral","genericName":"EI-1071 tablet, oral","slug":"ei-1071-tablet-oral","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMilAJBVV95cUxOSERqOXo3RmVqLWUzVzZROGdjeDdMWUJFRDFndFFuUEVKZVB1ZUFyN0trS3Q2ZkJZVC1BamQtdTBHYzlacGRqVTZIMC1tX04zc1NXV21URmlNSHlPMjMwYkozMHdacFVsNnljVURabG43YWo0bGdOSUlaNmVpZGVYWk5zZzREUDVSNFNaVVBodnQtSEdBLWRBRUNUM2ZzUldVUl85cGw2S0daYk9oLUFUQXFqdWJmdGh0d1JkTzh3anZORm5wMk5oZU55ZE5PN2FWYnBiQThGUW9waE10amtuSXMyQkYzaTdvckl3dHVQUERITlJzVmxKMnpNSDB4M1lpZ212cWQ1T3JVR2l6YVo1U3lLS3I?oc=5","date":"2025-03-04","type":"regulatory","source":"PR Newswire","summary":"Ono's ROMVIMZA Approval Shakes Up Tenosynovial Giant Cell Tumors Market, Challenging Daiichi Sankyo's TURALIO Dominance | DelveInsight - PR Newswire","headline":"Ono's ROMVIMZA Approval Shakes Up Tenosynovial Giant Cell Tumors Market, Challenging Daiichi Sankyo's TURALIO Dominance ","sentiment":"positive"}],"patents":[],"drugCount":2,"phaseCounts":{"phase_2":2},"enrichmentLevel":2,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}